TY - JOUR
TI - Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors
AU - Dimopoulou, D.
AU - Spyridis, N.
AU - Vartzelis, G.
AU - Tsolia, M.N.
AU - Maritsi, D.N.
JO - Arthritis and Rheumatology
PY - 2022
VL - 74
TODO - 2
SP - 365-366
PB - John Wiley and Sons Inc
SN - 2326-5191, 2326-5205
TODO - 10.1002/art.41977
TODO - adalimumab;  antirheumatic agent;  etanercept;  methotrexate;  tumor necrosis factor inhibitor, adolescent;  adverse event;  arthralgia;  disease exacerbation;  fatigue;  female;  headache;  human;  injection site reaction;  juvenile rheumatoid arthritis;  male;  myalgia;  prevention and control;  young adult, Adalimumab;  Adolescent;  Antirheumatic Agents;  Arthralgia;  Arthritis, Juvenile;  BNT162 Vaccine;  COVID-19;  Disease Progression;  Etanercept;  Fatigue;  Female;  Headache;  Humans;  Injection Site Reaction;  Male;  Methotrexate;  Myalgia;  SARS-CoV-2;  Tumor Necrosis Factor Inhibitors;  Young Adult
TODO - null
ER -